ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases
Portfolio Pulse from Benzinga Newsdesk
ProQR Therapeutics NV (NASDAQ:PRQR) announced new preclinical data for its Axiomer RNA editing technology, including proof of concept for its AX-0810 program targeting NTCP for cholestatic diseases. The data, presented at the ASGCT Annual Meeting, shows meaningful changes in biomarkers in NHPs, marking a significant step towards clinical trials. A management webinar is scheduled for May 9, 2024.
May 08, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProQR Therapeutics NV announced promising preclinical data for its AX-0810 program, indicating progress towards clinical trials for cholestatic diseases.
The announcement of positive preclinical data for ProQR's AX-0810 program targeting NTCP for cholestatic diseases is a significant development. This proof of concept in NHPs demonstrates the potential efficacy of the Axiomer RNA editing technology, which could lead to increased investor confidence and potentially positive movement in PRQR's stock price in the short term. The progress towards clinical trials, expected to begin in late 2024 or early 2025, further underscores the importance of this milestone.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100